Trial Number
190-21
Condition
Breast Cancer
Participant Age Range
18 years and older
Participant Gender
Female
Enrolling Participants
Yes
Overview
“The Impact of Cerianna PET/CT results on the Therapeutic Decision in Patients with Known or Suspected Metastatic Breast Cancer with ER Positive and HER2 Negative Primary Lesion”
This is a Phase 4, multi-center, non-randomized, open-label, prospective cohort study, with an adaptive design element to evaluate the impact of Cerianna on the management of patients by the detection of ER status in known or suspected MBC patients who receive either 1st line standard-of-care hormonal therapy or receive 2nd line standard-of-care hormonal therapy for a primary lesion characterized as ER-positive and human epidermal growth factor receptor 2 (HER2)-negative.